Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 15, 1997

View Archived Issues

Pharmacia & Upjohn describes HIV reverse transcriptase inhibitors

Japanese scientists report cholecystokinin antagonists

Potent antitumor agents described by Daiichi

Antifungal agent described by Roussel Morishita

New MDR modulators disclosed by Vertex

New antimigraine agent from Pfizer

PDE IV inhibitors revealed by Byk Gulden

New COX-2 inhibitor series reported by Merck Frosst

New PDE IV/TNF inhibitors from Chiroscience

Searle describes antiinflammatory oxazoles

Xoma expands pivotal Neuprex trials

Boston Life Sciences accelerates development of Altropane

AEterna accelerates anticancer clinical program

FDA proposes withdrawal of terfenadine products

Third set of phase III trials on Diatide imaging agent commences

Combination protease inhibitor trial with 141W94/VX-478

FDA clears antimetastatic carbohydrate compound for human trials

Aronex out-licenses antibody-toxin complex

Inhale/Centeon agreement for alpha1-proteinase inhibitor

SyStemix to be integrated into Novartis

Gene Logic/Baylor prostate cancer collaboration

Stanford researchers isolate breast cancer gene

Roche/Genentech marketing agreement for Roferon-A

3DP and ViroPharma establish drug discovery collaboration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...